PMID- 29460712
OWN - NLM
STAT- MEDLINE
DCOM- 20200703
LR  - 20200703
IS  - 1092-8529 (Print)
IS  - 1092-8529 (Linking)
VI  - 24
IP  - 3
DP  - 2019 Jun
TI  - Rhythmic low-field magnetic stimulation may improve depression by increasing 
      brain-derived neurotrophic factor.
PG  - 313-321
LID - 10.1017/S1092852917000670 [doi]
AB  - BACKGROUND: Low-field magnetic stimulation (LFMS) has mood-elevating effect, and 
      the increase of brain-derived neurotrophic factor (BDNF) is associated with 
      antidepressant treatment. We evaluated the effects and association with BDNF of 
      rhythmic LFMS in the treatment of major depressive disorder (MDD). METHODS: A 
      total of 22 MDD patients were randomized to rhythmic alpha stimulation (RAS) or 
      rhythmic delta stimulation (RDS), with 5 sessions per week, lasting for 6 weeks. 
      Outcomes assessments included the 17-item Hamilton Depression Rating Scale 
      (HAMD-17), the Hamilton Anxiety Rating Scale (HAMA), and the Clinical Global 
      Impressions-Severity scale (CGI-S) at baseline and at weeks 1, 2, 3, 4, and 6. 
      Serum BDNF level was measured at baseline and at weeks 2, 4, and 6. RESULTS: 
      HAMD-17, HAMA, and CGI-S scores were significantly reduced with both RAS and RDS. 
      RAS patients had numerically greater reductions in HAMD-17 scores than RDS 
      patients (8.9 +/- 7.4 vs. 6.2 +/- 6.2, effect size [ES]=0.40), while RDS patients had 
      greater improvement in HAMA scores (8.2 +/- 8.0 vs. 5.3 +/- 5.8, ES=0.42). RAS was 
      associated with clinically relevant advantages in response (54.5% vs. 18.2%, 
      number-needed-to-treat [NNT]=3) and remission (36.4% vs. 9.1%, NNT=4). BDNF 
      increased significantly during the 6-week study period (p<0.05), with greater 
      increases in RAS at weeks 4 and 6 (ES=0.66-0.76) and statistical superiority at 
      week 2 (p=0.034, ES=1.23). Baseline BDNF in the 8 responders (24.8+/-9.0 ng/ml) was 
      lower than in the 14 nonresponders (31.1+/-7.3 ng/ml, p=0.083, ES=-0.79), and BDNF 
      increased more in responders (8.9+/-7.8 ng/ml) than in nonresponders (1.8+/-3.5 
      ng/ml, p=0.044). The change in BDNF at week 2 was the most strongly predicted 
      response (p=0.016). CONCLUSIONS: Rhythmic LFMS was effective for MDD. BDNF may 
      moderate/mediate the efficacy of LFMS.
FAU - Xiao, Le
AU  - Xiao L
AD  - 1The National Clinical Research Center for Mental Disorders and Beijing Key 
      Laboratory of Mental Disorders,Beijing Anding Hospital,Capital Medical 
      University,Beijing,China.
FAU - Correll, Christoph U
AU  - Correll CU
AD  - 2Department of Psychiatry,The Zucker Hillside Hospital,Northwell Health,Glen 
      Oaks,New York,United States.
FAU - Feng, Lei
AU  - Feng L
AD  - 1The National Clinical Research Center for Mental Disorders and Beijing Key 
      Laboratory of Mental Disorders,Beijing Anding Hospital,Capital Medical 
      University,Beijing,China.
FAU - Xiang, Yu-Tao
AU  - Xiang YT
AD  - 3Unit of Psychiatry, Faculty of Health Sciences,University of Macau,Macao 
      SAR,China.
FAU - Feng, Yuan
AU  - Feng Y
AD  - 1The National Clinical Research Center for Mental Disorders and Beijing Key 
      Laboratory of Mental Disorders,Beijing Anding Hospital,Capital Medical 
      University,Beijing,China.
FAU - Hu, Chang-Qing
AU  - Hu CQ
AD  - 1The National Clinical Research Center for Mental Disorders and Beijing Key 
      Laboratory of Mental Disorders,Beijing Anding Hospital,Capital Medical 
      University,Beijing,China.
FAU - Li, Rena
AU  - Li R
AD  - 1The National Clinical Research Center for Mental Disorders and Beijing Key 
      Laboratory of Mental Disorders,Beijing Anding Hospital,Capital Medical 
      University,Beijing,China.
FAU - Wang, Gang
AU  - Wang G
AD  - 1The National Clinical Research Center for Mental Disorders and Beijing Key 
      Laboratory of Mental Disorders,Beijing Anding Hospital,Capital Medical 
      University,Beijing,China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180220
PL  - United States
TA  - CNS Spectr
JT  - CNS spectrums
JID - 9702877
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Adult
MH  - Alpha Rhythm
MH  - Brain/metabolism/physiopathology
MH  - Brain-Derived Neurotrophic Factor/genetics/*metabolism
MH  - Delta Rhythm
MH  - Depression/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Transcranial Magnetic Stimulation/*methods
OTO - NOTNLM
OT  - Major depressive disorder
OT  - brain-derived neurotrophic factor
OT  - mediator
OT  - moderator
OT  - rhythmic magnetic stimulation
EDAT- 2018/02/21 06:00
MHDA- 2020/07/04 06:00
CRDT- 2018/02/21 06:00
PHST- 2018/02/21 06:00 [pubmed]
PHST- 2020/07/04 06:00 [medline]
PHST- 2018/02/21 06:00 [entrez]
AID - S1092852917000670 [pii]
AID - 10.1017/S1092852917000670 [doi]
PST - ppublish
SO  - CNS Spectr. 2019 Jun;24(3):313-321. doi: 10.1017/S1092852917000670. Epub 2018 Feb 
      20.